Education
About Us
Working with TipRanks
Follow Us
Cadrenal Therapeutics, Inc. (CVKD)
:CVKD
Total Valuation
Cadrenal Therapeutics, Inc. has a market cap or net worth of $16.62M. The enterprise value is $24.41M.
Market Cap$16.62M
Enterprise Value$24.41M
Share Statistics
Cadrenal Therapeutics, Inc. has 2,338,127 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,338,127
Owned by Insiders51.58%
Owned by Institutions<0.01%
Financial Efficiency
Cadrenal Therapeutics, Inc.’s return on equity (ROE) is -1.43 and return on invested capital (ROIC) is -147.33%.
Return on Equity (ROE)-1.43
Return on Assets (ROA)-1.05
Return on Invested Capital (ROIC)-147.33%
Return on Capital Employed (ROCE)-1.47
Revenue Per Employee0.00
Profits Per Employee-2.66M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cadrenal Therapeutics, Inc. is ―. Cadrenal Therapeutics, Inc.’s PEG ratio is 0.18.
PE Ratio―
PS Ratio0.00
PB Ratio2.38
Price to Fair Value2.38
Price to FCF-2.40
Price to Operating Cash Flow-1.96
PEG Ratio0.18
Income Statement
In the last 12 months, Cadrenal Therapeutics, Inc. had revenue of 0.00 and earned -10.65M in profits. Earnings per share was -8.73.
Revenue0.00
Gross Profit-1.88K
Operating Income-10.96M
Pretax Income-10.65M
Net Income-10.65M
EBITDA-10.65M
Earnings Per Share (EPS)-8.73
Cash Flow
In the last 12 months, operating cash flow was -11.82M and capital expenditures -11.64K, giving a free cash flow of -11.83M billion.
Operating Cash Flow-11.82M
Free Cash Flow-11.83M
Free Cash Flow per Share-5.06
Dividends & Yields
Cadrenal Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.18
52-Week Price Change-56.03%
50-Day Moving Average11.52
200-Day Moving Average13.50
Relative Strength Index (RSI)33.75
Average Volume (3m)54.47K
Important Dates
Cadrenal Therapeutics, Inc. upcoming earnings date is Mar 18, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 18, 2026
Ex-Dividend Date―
Financial Position
Cadrenal Therapeutics, Inc. as a current ratio of 3.77, with Debt / Equity ratio of 0.00%
Current Ratio3.77
Quick Ratio3.77
Debt to Market Cap0.00
Net Debt to EBITDA0.94
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cadrenal Therapeutics, Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cadrenal Therapeutics, Inc. EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -1.04.
EV to Sales0.00
EV to EBITDA-0.72
EV to Free Cash Flow-1.04
EV to Operating Cash Flow-1.04
Balance Sheet
Cadrenal Therapeutics, Inc. has $3.86M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.86M billion.
Cash & Marketable Securities$3.86M
Total Debt$0.00
Net Cash$3.86M
Net Cash Per Share$1.65
Tangible Book Value Per Share$6.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cadrenal Therapeutics, Inc. is $45.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$45.00
Price Target Upside248.30% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-9.80%